U.S. Cell And Gene Therapy Cdmo Market Size & Outlook
- HC Outsourcing
- CMO/CDMO
- Cell And Gene Therapy CDMO Market Outlook
- CMO/CDMO
Global Market
Related Markets
Ask a question about the cell and gene therapy cdmo market
U.S. cell and gene therapy cdmo market highlights
- The U.S. cell and gene therapy cdmo market generated a revenue of USD 1,615.6 million in 2024 and is expected to reach USD 10,343.4 million by 2033.
- The U.S. market is expected to grow at a CAGR of 23.3% from 2025 to 2033.
- In terms of segment, pre-clinical was the largest revenue generating phase in 2024.
- Pre-clinical is the most lucrative phase segment registering the fastest growth during the forecast period.
Cell and gene therapy cdmo market data book summary
| Market revenue in 2024 | USD 1,615.6 million |
| Market revenue in 2033 | USD 10,343.4 million |
| Growth rate | 23.3% (CAGR from 2025 to 2033) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.5% of the global cell and gene therapy cdmo market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. cell and gene therapy cdmo market is projected to lead the regional market in terms of revenue in 2033.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 10,343.4 million by 2033.
Pharmaceutical companies are increasingly outsourcing their development & manufacturing activities to CDMOs to reduce costs, accelerate time-to-market, and access specialized expertise. This trend is expected to drive the cell and gene therapy CDMO market growth across the U.S.
This expansion includes investments in new facilities, equipment upgrades, mergers & acquisitions, and process improvements. For instance, in September 2023, Apprentice.io partnered with Minaris Regenerative Medicine, a leading CDMO for cell & gene therapies, to implement the Tempo Manufacturing Execution System (MES).
This initiative strengthens Minaris’ competitive position and promotes market growth. Some of the key companies providing pharmaceutical CDMO services in the U.S. are Catalent, Inc., Lonza, Aenova Group, AbbVie, Inc., and Adare Pharma Solutions. The growing presence of these companies expanding their manufacturing facilities to cater to the rising demand for pharmaceuticals is likely to propel market growth.
No credit card required*
Publish Date: Sep 08, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Samsung Electronics Co Ltd | View profile | 124,804 | 129, Samsung-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, Korea, Republic of, 443-742 | www.samsung.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| OmniAb Inc | View profile | 106 | 5980 Horton Street, Suite 600, Emeryville, CA, United States, 94608 | www.omniab.com |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| AGC Inc | View profile | 61,671 | 1-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan, 100-8405 | www.agc.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Rentschler Biopharma SE | View profile | 501-1000 | Laupheim, Baden-Wurttemberg, Germany, Europe | www.rentschler-biopharma.com |
U.S. Cell And Gene Therapy CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy CDMO Market Outlook will help companies and investors design strategic landscapes.
Pre-Clinical was the largest segment with a revenue share of 78.5% in 2024.
Horizon Databook has segmented the U.S. cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2021 to 2033.
Pharmaceutical companies are increasingly outsourcing their development & manufacturing activities to CDMOs to reduce costs, accelerate time-to-market, and access specialized expertise. This trend is expected to drive the cell and gene therapy CDMO market growth across the U.S.
This expansion includes investments in new facilities, equipment upgrades, mergers & acquisitions, and process improvements. For instance, in September 2023, Apprentice.io partnered with Minaris Regenerative Medicine, a leading CDMO for cell & gene therapies, to implement the Tempo Manufacturing Execution System (MES).
This initiative strengthens Minaris’ competitive position and promotes market growth. Some of the key companies providing pharmaceutical CDMO services in the U.S. are Catalent, Inc., Lonza, Aenova Group, AbbVie, Inc., and Adare Pharma Solutions. The growing presence of these companies expanding their manufacturing facilities to cater to the rising demand for pharmaceuticals is likely to propel market growth.
- U.S. Cell And Gene Therapy Cdmo Market Phase Outlook (Revenue, USD Million , 2021-2033)
- Pre-clinical
- Clinical
- U.S. Cell And Gene Therapy Cdmo Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Rare Diseases
- Others
- Oncology
- Infectious Diseases
- Neurological disorders
- U.S. Cell And Gene Therapy Cdmo Market Product Type Outlook (Revenue, USD Million , 2021-2033)
- Gene Therapy
- Gene-Modified Cell Therapy
- Cell Therapy
Reasons to subscribe to Cell And Gene Therapy CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy CDMO Market Outlook databook
- Our clientele includes a mix of Cell And Gene Therapy CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Cell And Gene Therapy CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Cell And Gene Therapy CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Cell And Gene Therapy Cdmo Market, 2021-2033 (US$M)
U.S. cell and gene therapy cdmo market statistics, by phase, 2021-2033 (US$M)
